Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.

Blood - 1 Jan 2026

Brown Jennifer R, Nguyen Bastien, Desikan Sai Prasad, Won Helen, Tantawy Shady I, McNeely Samuel C, Marella Narasimha, Randeria Hetal S, Hanson Lauren M, Parker Andrew, Botelho Salomé Calado, Woyach Jennifer A, Patel Krish, Tam Constantine S, Eyre Toby A, Cheah Chan Y, Shah Nirav N, Ghia Paolo, Jurczak Wojciech, Balbas Minna, Nair Binoj, Abada Paolo, Wang Chunxiao, Wang Denise, Roeker Lindsey E, Gandhi Varsha, Wierda William G

Abstract excerpt

ABSTRACT: Pirtobrutinib, a noncovalent, reversible Bruton tyrosine kinase inhibitor (BTKi), demonstrated efficacy in patients with chronic lymphocytic leukemia (CLL), resistant to covalent BTKi (cBTKi). We analyzed genomic correlations with response and resistance to pirtobrutinib in relapsed/refractory (R/R) patients with CLL pretreated with cBTKi enrolled in the phase 1/2 BRUIN trial. DNA sequencing was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Drug Resistance, Neoplasm

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyrimidines

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 41055698
DOI: 10.1182/blood.2024027009
PMCID: PMC12824664

Genes

BTK
ATM
BCL2
NOTCH1
PLCG2
SF3B1
TP53
XPO1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.PMID 41055698Read ↗

Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read ↗

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapySemantic proximity Read ↗

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.Semantic proximity Read ↗

Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib.Semantic proximity Read ↗

Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progressionSemantic proximity Read ↗

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read ↗

Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitorsSemantic proximity Read ↗

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSemantic proximity Read ↗

Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.Semantic proximity Read ↗

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read ↗

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.